This explains why ex vivo graft engineering, i.e., depleting CD276+ cells after donor recipient MLC dramatically decreased the severity of GVHD in an HLA-mismatched setting but did not improve the clinical outcome in an HLA-matched xeno-GVHD model. This evidence concerns the gene CD276 and graft versus host disease.